Many of the therapeutic advances in the treatment of cancer and related diseases are a result of collaborative efforts, and specifically, cooperative group studies. Because of this, the University of Mississippi Medical Center has been an active participant in the Southwest Oncology Group since 1971. The University of Mississippi Medical Center can best utilize its resources and offer our patients access to new cancer treatment, prevention and cancer control studies through full participation in the Southwest Oncology Group. Our collaborative efforts include participation in the Southwest Oncology Group's Cooperative Group Outreach Program. A multidisciplinary approach to the management of patients is employed by a team of medical oncologists, hematologists, radiation oncologists, surgeons and surgical subspecialties, pathologists, and cancer prevention and dental researchers. A centralized system for management of data on cancer clinical trials is in place at the institution. Trained clinical trials coordinators and nurses are actively involved in identifying patients for study participation and monitoring patients placed on studies. Institutional investigators actively participate in disease, discipline, standing and administrative committees of the Southwest Oncology Group. Group-wide leadership is demonstrated by this institution's chairing of the Clinical Research Associates Committee, participation in disease committee working groups, and the Board of Governors. The institution continues to serve as the depot pharmacy for an intergroup prostate cancer study. Minorities, primarily African-Americans, comprised approximately 45% of registrations during the period 1992 to 1996. The high percentage of minorities registered on clinical trials should continue during the next grant period. Over the next five years, the University of Mississippi Medical Center plans to increase its accrual to studies, maintain our standards of excellence in the management of data, and increase the level of participation by investigations in committee activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA016385-24
Application #
2456977
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1978-01-01
Project End
2002-12-31
Budget Start
1998-04-09
Budget End
1998-12-31
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Mississippi Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 124 publications